Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Exam 4-DWB > Hepatitis B, C, D, E > Flashcards

Hepatitis B, C, D, E Flashcards

1
Q

Hepatitis B transmission

A
  1. blood borne
  2. sexually transmitted
  3. can live on environmental surfaces for up to 7 days
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which body fluids have high viral concentration

A
  1. blood
  2. serum
  3. wound exudates
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which body fluids have moderate viral concentrations

A
  1. semen
  2. vaginal fluid
  3. saliva
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which body fluids have low/not detectable

A
  1. urine
  2. feces
  3. sweat
  4. tears
  5. breast milk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Worldwide at-risk population for hepatitis B

A
  1. endemic countries such as asia, sub-saharan africa
  2. children of HBV-positive mothers
  3. travelers to endemic areas
  4. sexual contacts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

US at-risk population for hepatitis B

A
  1. sexual contacts
  2. household contacts
  3. IV drug users
  4. health care workers
  5. people working with /receiving blood products or dialysis
  6. residents/staff of facilities for developmentally disabled persons
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

There is an increased prevalence of Hepatitis B in what populations

A
  1. HIV + persons
  2. IV drug users
  3. men having sex with men
  4. sexual/household contacts of HBsAg + persons
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Who should get tested for hepatitis B

A
  1. anyone with acute presentation of liver disease

2. anyone in risk groups

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

acute hepatitis B infection: incubation

A

30-180 days, mean 60-90

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HPI/ROS of acute hepatitis B infection

A
  1. General: fatigue, low-grade fever
  2. Skin: erythematous rash, urticaria
  3. HEENT: jaundice at day 10
  4. GI: nausea, bloated feeling
  5. MS: arthralgias
  6. VS: fever
  7. Skin: rash, jaundice
  8. HEENT: posterior cervical lymph nodes, icteric sclera
  9. GI: tender, palpable liver edge {70%}
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Surface antigen and antibody for hepatitis B

A

Antigen- HBsAg

Antibody- anti-HBs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Core antigen and antibody for hepatitis B

A

Antigen- HBcAg

Antibody - anti-HBc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

e=nucleocapsid protein {similar to C}

A

Antigen: HBeAg
Antibody: anti-HBe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Polymerase chain reaction test for viral load of hepatitis B

A
  1. DNA amplification technique able to detect as few as copies/mL
  2. very expensive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Indications of viral load test

A
  1. treatment decisions
  2. response to treatment
  3. chronic infection
  4. unusual presentation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Prevalence of chronic HBV

A
  1. two billion people have incidence of infection
  2. 800,000 - 1.4 million infected in US
  3. ninth leading cause of death worldwide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What percent of children and adults with chronic hepatitis B infections will develop cirrhosis or liver cancer

A

25% of childhood

15% of adults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Antigens and antibodies for chronic Hepatitis B infection

A
  1. HBsAg positive for > 6 months;
  2. total anti-HBc positive;
  3. HBeAg may have significance in long-term clinical course;
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Hepatitis D infection always requires what other infection and why

A

HBV infection because it uses HBV protein shell;

** can occur acutely as a co-infection with HBV or as a superinfection after HBV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the most common blood-borne infection in the US

A

Hepatitis C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How is hepatitis C spread

A

parenteral route

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What percent of patients with hepatitis C develop chronic liver disease

A

40-60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Risk groups for hepatitis C

A
  1. current/former injection drug user
  2. pre 1987 clotting factor recipients
  3. pre-1992 transfusion/organ recipient
  4. dialysis patient
  5. person with known HCV exposure
  6. person with HIV/HBV
  7. children born to HCV + mother
  8. persons born between age of 1945-1965
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Clinical course for hepatitis C

A
  1. incubates over 6-7 months
  2. 25% of people develop jaundice
  3. 1% mortality rate in acute infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
symptoms of hepatitis C
typically asymptomatic, indolent, prolonged course until advanced liver disease develops
26
Who should get tested for hepatitis C
1. ever injected illegal drugs 2. infected with HIV/HBV 3. unexplained abnormal ALT/liver disease 4. born to HCV + mother 5. ever on hemodialysis 6. needlestick 7. sexual partner to HCV + person 8. received clotting factors made before 1987 or blood/organs before 1992 9. born between 1945-1965
27
Lab testing for hepatitis C
1. screens for HCV antibodies 2. detects antibodies 28-90 days after exposure 3. does not distinguish acute from chronic 4. misses approximately 10% of positives 5. may see ALT fluctuate wildly and does not predict the extent of liver damage 6. follow positive screening result with confirmatory testing
28
hepatitis C viral load
PCR: HCV RNA+ one to two weeks after infection Indication: acute infection suspected anti-HCV ambiguous or unconfirmed, infection suspected with normal LFTs - repeat if negative with high suspicion of infection - no sure correlation between high titer and disease severity
29
Genotyping testing for HCV
1. informs treatment decisions 2. type 1 HCV most common in US 3. type 2 and 3 most likely to respond to treatment {24 weeks}; 4. type 1 more resistant to treatment {48 weeks}
30
Cofactors for hepatitis C disease severity
1. alcohol 2. age over 40 at time of infection 3. HIV coinfection 4. male 5. other coinfection
31
Out of every 100 people infected how many with hepatitis C will develop chronic infection
75-80
32
Out of every 100 people infected how many with hepatitis C will develop chronic liver disease
60-70
33
Out of every 100 people infected how many with hepatitis C will develop cirrhosis over 20-30 years
5-20
34
Out of every 100 people infected how many with hepatitis C will die from infection consequences
1-5
35
What are the extrahepatic manifestations of hepatitis C
1. lymphoma 2. diabetes 3. glomerulonephritis 4. porphyria cutanea tarda 5. lichen planus
36
Chronic HBV treatment is based on
1. ALT abnormality 2. viral load 3. positive/negative E antigen 4. abnormal liver biopsy
37
Chronic HBV treatment is aimed at
viral replication; 1. pegylated interferon and ribavirin 2. protease inhibitors: a. adefovir, b. entecavir, c. telbivudine, d. tenofovir; e. lamivudine {virus may become resistant
38
E antigen-negative treatment for Hepatitis B when normal ALT, viral lode under 10^5
1. no treatment | 2. follow with LFTs, alpha fetoprotein every 6 months
39
E antigen-negative treatment for Hepatitis B when abnormal ALT, viral load > 10^5
GI referral for treatment consideration
40
Chronic HCV treatment
1. Ribavirin 2. pegylated interferon 3. telaprevir 4. boceprevir 5. simeprevir 6. sofosbuvir
41
What is the duration for chronic HCV treatment
6-12 months
42
Duration for chronic HCV treatment depends on
1. genotype 2. viral load 3. liver biopsy results
43
Side effects of chronic HCV treatments
1. nausea 2. fatigue 3. irritability 4. hair loss 5. anemia 6. neutropenia
44
interactions of chronic HCV treatments
multiple drug-to-drug interactions because of cytochrome P450
45
hepatocellular carcinoma is associated with
HBV and HCV
46
testing with hepatocellular carcinoma
alpha fetoprotein, liver US every 6 months
47
Liver transplant and HBV re-infection treatments
1. HBIG: improved outcomes but expensive 2. Famciclovir: less promising 3. Lamivudine: greater resistance 4. Combination therapy: HBIG, vaccine
48
Liver transplant and HCV reinfection treatments
1. recurrent infection almost universal 2. graft damage related to degree of immune suppression 3. viral activity continues with immunosuppressants
49
Education/Prevention plan for Hepatitis
1. safe sex 2. clean needles 3. universal precautions 4. health promotion in those infected 5. avoid alcohol/unnecessary medications/infection
50
Screening for hepatitis C should be done
1. high risk groups | 2. baby boomers 1945-1965
51
Vaccinations for HAV/HBV should be done for
1. risk groups: STD clinics, HIV counseling/testing sites; 2. correctional facilities; 3. drug treatment clinics 4. sexual and household contacts 5. healthcare workers/first responders 6. diabetics
52
HAV vaccine candidates
1. all children 12-23 months 2. unvaccinated adolescents, young adults 3. IV drug users 4. men who have sex with men 5. travelers 6. persons with any other chronic hepatitis 7. clotting factor recipients 8. persons who work with primates
53
Hepatitis A vaccines
different formulas for: 1. pediatric {12 months-18 years} 2. adult > 18 years 100% immunogenic
54
Common side effects for hepatitis A vaccine
1. soreness at injection site | 2. headache
55
Where is the hepatitis A vaccine given
deltoid injections for adults/adolescents; | for child: vastus lateralus
56
Hepatitis A vaccine and other vaccines
safe to give with other immunizations but use separate site
57
Hepatitis A vaccine dosing for travelers
1. four weeks before travel give 1 dose 2. less than 4 weeks before travel: dose one plus 0.02mg/kg immune globulin (Ig) IM at different site; 3. give second dose 6-12 months after dose one for long-term protection
58
Do you test first before giving hepatitis A vaccine for traveling
yes if adult is > 40 born in or with history of travel to HAV-endemic areas
59
Postexposure prophylaxis for hepatitis A is given when
within 2 weeks of exposure
60
To whom do you give Postexposure prophylaxis for hepatitis A
if 40 +,health problems: immune globulin for passive protection;
61
What hepatitis A vaccine do you give to high risk groups
both vaccine and immune globulin
62
Candidates for HBV vaccine
1. infants at birth 2. catch up all others < 19 3. multiple sex partners, MSM, STDs, HIV, HCV, chronic HBV+ sexual partners; 4. healthcare workers 5. IV drug users 6. dialysis patients 7. diabetes age 19-59 {higher incidence/poorer outcomes} 8. travelers
63
Do you test first for HBV vaccine
1. consider prevalence in pt population {high risk sex, IVDU, immigrant}; 2. consider cost of testing {HBsAg} including visit and vaccine
64
When do you do HBV testing after HBV vaccine
1. ongoing risk of exposure 2. healthcare worker 3. high risk sex 4. IVDU 5. infected household 6. obese 7. in 4-8 weeks after 3rd vaccine dose 8. anti-HBs 9. full series vaccine for nonresponders 10. copy of antibody titer lab results to patients
65
When do you not do HBV testing after HBV vaccine
infant, child, adolescent
66
HBV booster doses are recommended
only for hemodialysis patients 1. test annually for anti-HBs 2. administer booster if level < 10
67
HBV booster for immunocompromised patients
undetermined need but consider annual anti-HBs testing and booster if level < 10
68
HBV booster is not recommended for
vaccinated persons with normal immunity, low exposure risk
69
Post-exposure prophylaxis for known HBsAG + source
1. as soon as possible, ideally within 24 hours
70
Post-exposure prophylaxis for known HBsAG + source booster dose
persons with written documentation of complete HBV vaccine series but no postvaccination testing
71
Post-exposure prophylaxis for known HBsAG + sourceHBIG and finish vaccine series on normal schedule
persons in vaccination process
72
Post-exposure prophylaxis for known HBsAG + source vaccine and HBIG
unvaccinated persons 1. simultaneous administration, separate injection site 2. vaccine series according to age-appropriate dose/schedule
73
Post-exposure prophylaxis for unknown HBsAG: no treatment
persons with written documentation of completed HBV vaccination series
74
Post-exposure prophylaxis for unknown HBsAG: vaccine series continued to completion
persons not fully vaccinated
75
Post-exposure prophylaxis for unknown HBsAG: vaccine series started as soon as possible
unvaccinated persons

Exam 4-DWB (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions